High-intensity training following lung cancer surgery: a randomised controlled trial

Thorax ◽  
2014 ◽  
Vol 70 (3) ◽  
pp. 244-250 ◽  
Author(s):  
E. Edvardsen ◽  
O. H. Skjonsberg ◽  
I. Holme ◽  
L. Nordsletten ◽  
F. Borchsenius ◽  
...  
BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e017307 ◽  
Author(s):  
Hélène Laurent ◽  
Géraud Galvaing ◽  
Emilie Thivat ◽  
Emmanuel Coudeyre ◽  
Sylvie Aubreton ◽  
...  

IntroductionSurgery is the standard curative treatment for lung cancer but is only possible in patients with local tumour and preserved exercise capacity. Improving fitness before surgery can reduce postoperative complications and mortality. However, preoperative rehabilitation remains difficult to implement for several reasons. We aim to investigate the effectiveness of an intensive 3-week home-based preoperative exercise training programme on hospital discharge ability, postoperative complications and physical performance in patients with chronic obstructive pulmonary disease (COPD) who are eligible for lung cancer surgery.Methods and analysisWe designed a multicentre randomised controlled trial. The randomisation sequence will be generated and managed electronically by a research manager independent of assessments or interventions. We will recruit 90 patients with COPD and a diagnosis of lung cancer from four university hospitals. The rehabilitation group (R group) will receive a standardised preoperative home exercise programme for 3 weeks, combining both high-intensity training and usual physical therapy. The R group will perform 15 training sessions over 3 weeks on a cycloergometer. A physical therapist experienced in pulmonary rehabilitation will visit the patient at home and supervise one session a week. The R group will be compared with a control group receiving preoperative usual physical therapy only. The primary outcome will be hospital discharge ability assessed with a 10-item list. Secondary outcomes will be postoperative course (complication rate and mortality) as well as pulmonary function, exercise capacity and quality of life assessed 1 month before and the day before surgery.Ethics and disseminationThis protocol has been approved by the French health authority for research (2016-A00622-49) and the research ethics committee/institutional review board (AU1267). Adverse events that occur during the protocol will be reported to the principal investigator. The results will be published in an international peer-reviewed journal.Trial registration numberNCT03020251.


Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Aron Onerup ◽  
Eva Angenete ◽  
David Bock ◽  
Mats Börjesson ◽  
Monika Fagevik Olsén ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


Author(s):  
Aristea Gioxari ◽  
Dimitrios Tzanos ◽  
Christina Kostara ◽  
Panos Papandreou ◽  
Giannis Mountzios ◽  
...  

The Mediterranean diet (MD) has been inversely associated with lung cancer (LC) risk. Hereby we show the preliminary results of our prospective randomised controlled trial in inflammatory and nutritional status of LC patients after 3-month implementation of MD. In total, 30 patients with small-cell or non-small-cell LC (stages III–IV) were enrolled. They were randomly assigned either to Control group, receiving general nutritional guidelines, or the MD group, in which a personalised MD plan was provided. Medical and dietary history, anthropometrics, blood biomarkers, and circulating antioxidant vitamins were assessed. The main outcome was a significantly higher advanced lung cancer inflammation index (ALI) in patients of the control arm than those following MD (p = 0.003). In the MD group, platelets were significantly reduced at the study endpoint (p = 0.044). BMI and body fat mass remained unchanged in both arms, but serum glucose was significantly higher in control compared to MD group (p = 0.017). In conclusion, we showed for the first time that implementing a personalised MD for 3 months is promising to regulate prognostic biomarkers in advanced LC. The final results of our on-going trial will shed a light on the inflammatory, antioxidant and nutritional status of LC patients following MD.


Sign in / Sign up

Export Citation Format

Share Document